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Monitoring of internal exposure for nuclear medicine workers requires frequent measurements due to the short physical half-
lives of most radionuclides used in this field. The aim of this study was to develop screening measurements performed at the
workplace by local staff using standard laboratory instrumentation, to detect whether potential intake has occurred. Such
measurements do not enable to determine the committed effective dose, but are adequate to verify that a given threshold is
not exceeded. For radioiodine, i.e. 123I, 124I, 125I and 131I, a calibrated surface contamination monitor is placed in front of
the thyroid to detect whether the activity threshold has been exceeded. For radionuclides with very short physical half-lives
(6 h), such as 99mTc and those used in positron emission tomography imaging, i.e. 11C, 15O, 18F and 68Ga, screening pro-
cedures consist in performing daily measurements of the ambient dose rate in front of the abdomen. Other gamma emitters
used for imaging, i.e. 67Ga, 111In and 201Tl, are measured with a scintillation detector located in front of the thorax. For pure
beta emitters, i.e. 90Y and 169Er, as well as beta emitters with low-intensity gamma rays, i.e. 153Sm, 177Lu, 186Re and 188Re,
the procedure consists in measuring hand contamination immediately after use. In Switzerland, screening procedures have
been adopted by most nuclear medicine services since such measurements enable an acceptable monitoring while taking into
account practical and economic considerations.
INTRODUCTION
Workers who may accumulate an effective dose .1
mSv y–1 are considered as occupationally exposed
to ionising radiation. Unless the internal exposure
contributes to ,10 % of the total, i.e. external and
internal, annual effective dose or to ,0.1 mSv y–1,
individual monitoring for internal exposure is
required(1). As illustrated in Figure 1, the monitoring
of Swiss workers with a risk of intake is based on a
two-stage measurement process as follows:(1, 2)
(i) ‘screening measurements’ performed at the
workplace by local staff to detect whether
potential intake has occurred; and
(ii) ‘intake measurements’ performed by an
approved dosimetry service to determine the
committed effective dose, E50, in the case of
positive screening results.
Screening measurements are particularly suitable
for monitoring nuclear medicine workers since the
short half-lives of most radionuclides used in this
field impose frequent measurements. In contrast to
intake measurements, screening measurements are
meant to be performed on site using commonly avail-
able laboratory instruments and thus do not require
complex and expensive equipments for accurate
quantitative analysis, such as whole body counters.
The aim of this work was to develop practical
screening procedures for most radionuclides used in
nuclear medicine, including gamma emitters and bþ
emitters used for imaging, as well as b2 emitters
used for therapy.
MATERIALS AND METHODS
The screening procedure consists of a simple, rough
measurement that does not enable one to calculate
E50, but is sufficient to verify that a given threshold
is not surpassed. The screening threshold is chosen
to detect and not miss significant intake, as well as
to avoid standard intake measurement in the case of
negligible intake. The threshold is specific to the
radionuclide and is defined in such a way that the
annual E50 is ,1 mSv, in most cases, if the threshold
is never exceeded over the year. The dose criterion is
generally based on the inhalation pathway in order
to address conservative exposure scenarios.
Assuming that intake occurs in the middle of the
screening interval t, the screening threshold S (in
Bq) is given by the following expression:
S ¼ E50
NðtÞ 
mðt=2Þ
einh
ð1Þ
where N(t) is the number of screening measurements
per year, m(t/2) is the retention fraction given in
ICRP 78(3) and (4), i.e. the fraction of the activity
remaining in the whole body or in an organ at a
time t ¼ t/2, derived from standard biokinetic
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models, and einh is the effective dose coefficient for
inhalation obtained from ICRP 68(5). Four groups
of radionuclides are differentiated to develop specific
screening procedures: radioiodine, gamma emitters,
bþ emitters and b2emitters.
Screening procedure for radioiodine
Threshold values for 123I, 124I, 125I and 131I are
determined according to Equation (1). The retention
of activity in the thyroid is to be considered in the
case of iodine. For the screening procedure, a
surface contamination monitor (SCM), which is
available in any nuclear medicine service, is placed
in front of the thyroid to detect whether the
threshold is exceeded. The calibration procedure of
the SCM used for screening measurements is
described elsewhere(6). Briefly, the method consists in
measuring the response of the SCM to a known
activity of radioiodine located in the thyroid of a
standard neck phantom. The calibration factor in
becquerel per count per second (cps) is then
obtained, and the threshold can be determined in
cps specifically for each SCM.
Screening procedure for gamma emitters
For 67Ga, 111In and 201Tl, threshold values are
based on the whole body retention. Screening
measurements are performed using a lung monitor
(LM) that consists of a properly calibrated scintil-
lation detector positioned in front of the chest. The
calibration procedure is based on the response of the
LM to a known activity located in a simple trunk
phantom. The threshold is then determined in cps
for a given LM.
For 99mTc, because of the very short half-life
(T1/2 ¼ 6 h), daily measurements are required.
Therefore, a very simple screening approach based on
ambient dose rate measurement is introduced. First,
it was assumed that after a few hours the radio-
nuclide is mainly localised in the abdomen.
Positioning a dose rate meter in front of the abdomen
(at stomach level) leads to a measured ambient dose
rate _H
ð10Þ which may be related to the activity
threshold S as follows:
_H
ð10Þ ¼ S 
_hð10Þ
r2
¼ E50
NðtÞ 
2ðt=2Þ=T1=2
einh
 k 
_hð10Þ
r2
ð2Þ
where _hð10Þ is the effective dose rate coefficient for
external irradiation(7, 8) and r is the distance between
the source, i.e. the abdomen, and the detector
(7 cm). The attenuation within the body is assumed
negligible. The correction factor k takes into account
for a measurement in a non-point-source geometry
due to the distribution of the radionuclide within the
body. The factor k was analytically estimated by the
ratio of fluence rates between simple planar sources
and a point source at a distance r. For various planar
sources mimicking different retention patterns in the
abdominal region, k-values between 0.2 and 0.8 were
found and a generic value of 0.5 was finally adopted.
For daily measurements, N(t) corresponds to the
number of working days per year, i.e. 200.
Screening procedure for b1emitters
The ambient dose rate approach described in
Equation (2) is also suitable for bþ emitters that
show low values of einh (low radiotoxicity) and high
values of _h
ð10Þ (strong exposure rate due to 511 keV
annihilation radiation). However, since bþemitters
used for positron emission tomography are even
shorter-lived radionuclides than 99mTc, screening
measurements are required twice a day, in the middle
and at the end of the working day. For 15O, monitor-
ing of contamination in the breathing air must be
implemented at the workplace because of the only 2
min half-life. Screening measurements are then only
performed if a given air contamination threshold has
been exceeded (alarm).
Screening procedure for b2emitters
For pure b2emitters, i.e. 90Y and 169Er, as well as
beta emitters with low-intensity gamma rays,
i.e. 153Sm, 177Lu, 186Re and 188Re, screening measure-
ments are usually combined with standard intake
measurements, i.e. liquid scintillation counting of
activity in urine. However, because of the short half-
life of b2emitters used in nuclear medicine, weekly
measurements would be required. Furthermore,
because of the relatively high radiotoxicity of those
b2emitters, the activity threshold to be measured is
Figure 1. Concept for monitoring Swiss workers with a
risk of internal contamination based on (i) screening
measurements and (ii) intake measurements.
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so low that a chemical separation of the radionuclide
in the urine is often required before measurement.
Such a screening method is clearly cost-ineffective
and unrealistic for monitoring intake of b2emitters.
Since most radiopharmaceuticals labelled with
b2emitters are non-volatile, one may consider the
use of ingestion instead of inhalation as the relevant
pathway. The screening procedure is then simply
based on measurements of hand contamination
immediately after each use of the radionuclide. The
screening threshold S (in Bq cm22), is defined in
such a way that a daily ingestion of 1 % of the
threshold over 100 cm2 of the hands leads to E50 of
1 mSv. The threshold is then calculated as follows:
S ¼ E50
NðtÞ  eing  100 
1
1%
ð3Þ
where eing is the effective dose coefficient for inges-
tion(4). A daily use is assumed and N(t) is set to 200.
RESULTS AND DISCUSSION
Practical screening procedures for most radio-
nuclides used in nuclear medicine are summarised in
Table 1. The different approaches applied to radioio-
dine, gamma emitters, bþ emitters and b2emitters
are discussed.
Screening procedures for radioiodine
For 123I, 124I, 125I and 131I, the screening procedure
consists in measuring the activity threshold using a
calibrated SCM placed in front of the thyroid. For
123I and 125I, the threshold given in Table 1 corre-
sponds to an intake that leads to a minimum detect-
able E50 of 1 mSv, considering repetitive intake in
the middle of the screening interval. For 124I and
131I, it is not the case and, according to Equation
(1), the threshold for a weekly screening should be
260 and 190 Bq, respectively. On the other hand,
typical SCMs used for screening have a minimum
detectable activity of 3000 Bq for 124I and 2000
Bq for 131I. Therefore, in practice, a threshold of
3000 Bq is used for 124I and 2000 Bq for 131I, with a
screening interval of 1 week. Although the dose
limit of 1 mSv y–1 is not strictly guaranteed, this
choice is considered optimal since it ensures a low
rate of false positives and, because of the high
measurement frequency, a high probability of detect-
ing a significant intake.
Screening procedures for gamma emitters
For 67Ga, 111In and 201Tl, screening measurements
are performed using a properly calibrated LM. Since
an LM is often not available in nuclear medicine
services, the use of the dose rate approach for those
nuclides is also being considered. Corresponding dose
rate thresholds calculated according to Equation (2)
are given in Table 2. Note that in the case of 99mTc,
although Equation (2) yields a value of 0.19 mSv h–1,
a practical threshold of 1 mSv h–1 has been chosen to
avoid false positives while keeping a high probability
of detecting a significant intake.
Table 1. Screening procedures for most commonly used
radionuclides in nuclear medicine with the method of
measurement, the screening interval, the threshold value and
the minimum detectable annual E50 (E50,min).
Nuclide Method Interval Threshold E50,min
(in mSv)
11C DRMa 4 h 1 mSv h–1 5.0
15O DRMa by alarme 1 mSv h–1 2.9
18F DRMa 4 h 1 mSv h–1 4.8
67Ga LMb 7 d 5500 Bq 1.0
68Ga DRMa 4 h 1 mSv h–1 7.1
90Y HCMc each use 3000 Bq cm–2 1.6
99mTc DRMa 12 h 1 mSv h–1 5.3
111In LMb 7 d 5000 Bq 1.0
123I SCMd 1 d 1400 Bq 1.0
124I SCMd 7 d 3000 Bq 11.5
125I SCMd 30 d 1300 Bq 1.0
131I SCMd 7 d 2000 Bq 10.5
153Sm HCMc each use 3000 Bq cm–2 0.4
169Er HCMc each use 10 000 Bq cm–2 0.7
177Lu HCMc each use 3000 Bq cm–2 0.3
186Re HCMc each use 3000 Bq cm–2 0.9
188Re HCMc each use 3000 Bq cm–2 0.8
201Tl LMb 14 d 55 000 Bq 1.0
aDRM, dose rate monitor (abdomen/stomach).
bLM, lung monitor.
cHCM, hand contamination monitor (over 100 cm2).
dSCM, surface contamination monitor (thyroid).
eBy alarm, air contamination at workplace above
4000 Bq m–3.
Table 2. Dose rate approach for screening measurements of
gamma emitters and b1emitters.
Nuclide T1/2,phys einh (in Sv
Bq21)
_hð10Þ (in
mSv m2 per
h GBq)
_H
ð10Þ (in
mSv h21)
11C 20 min 3.210212 0.160 0.20a
15O 2 min 6.710213 0.160 0.34b
18F 110 min 9.310211 0.160 0.21a
68Ga 68 min 8.110211 0.149 0.14a
99mTc 6 h 2.910211 0.025 0.19c
67Ga 78 h 2.810210 0.022 0.04c
111In 67 h 3.110210 0.082 0.13c
201Tl 72 h 7.610210 0.018 0.11c
aScreening interval of 4 h.
bPost-alarm interval of 15 min. (2 alarms per day)
cScreening interval of 12 h (daily measurement).
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Screening procedures for b1emitters
The screening procedure for 11C, 15O, 18F and 68Ga
consists in frequent measurement of the ambient
dose rate in front of the stomach. Similar to 99mTc,
practical threshold values have been set to 1 mSv h–1
for all those radionuclides even though theoretical
threshold values given in Table 2 range between 0.14
and 0.34 mSv h–1.
Screening procedures for b2emitters
For 90Y, 153Sm, 169Er, 177Lu, 186Re and 188Re, the
screening procedure consists in measuring the con-
tamination of hands immediately after handling,
after removal of gloves. Threshold values given in
Table 1 are not exactly derived from Equation (3).
For practical reasons, threshold values were set to
1000 times the reference value for the maximum per-
missible level of surface contamination given in the
Swiss Ordinance on Radiation Protection(7). As a
result, E50 ranges between 0.3 and 0.9 mSv for all
those emitters except for 90Y (1.6 mSv).
Application in nuclear medicine
Screening procedures for most radionuclides used in
nuclear medicine are now included in the Swiss
Personal Dosimetry Ordinance(1) as an alternative
method to intake measurements. If the screening
threshold is exceeded, then a contact with an
approved internal dosimetry service must be estab-
lished to assess E50 using thyroid counting (radioio-
dine), whole body counting (gamma emitters) or
urine analysis (b2emitters). For 11C, 15O, 18F, 68Ga
and 99mTc, screening measurements are mandatory
since intake measurements are not possible because
of the very short physical half-lives. Note that the
threshold for 11C, 15O, 18F and 68Ga has been set to
0.1 mSv h–1 in the current Swiss Personal Dosimetry
Ordinance and might be adapted to 1 mSv h–1 in
the future. Usually, nuclear medicine services are not
interested in routine monitoring with standard
intake measurements because of the strict quality
control requirements and demands concerning the
ability to determine E50. Practically, screening pro-
cedures of any radionuclide used in nuclear medicine
can be achieved by a single measurement based on
an instrument equipped with properly calibrated
SCMs for the hands and the thyroid, and a dose rate
meter positioned at the stomach level. In
Switzerland, all results of screening measurements
must be locally registered. Individuals who are moni-
tored for internal exposure by screening measure-
ments are not registered in the National Dose
Registry unless an intake measurement has been per-
formed following a positive screening(9). In case of
continuous negative screening over the year, E50 is
recorded as zero in the individual dose document.
CONCLUSIONS
Screening measurements for detecting potential
radioactivity intake by nuclear medicine workers
enable an acceptable monitoring while taking into
account practical and economic considerations.
Since screening measurements are performed directly
at the workplace with standard laboratory equip-
ment, either a contamination monitor or a dose rate
meter, they have been implemented in most nuclear
medicine services in Switzerland at reasonable cost.
The authority is currently auditing those services
to ensure the proper execution of screening
measurements.
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